Monthly Archives: January 2016

Biotech Venture Data: Disappearing Crossovers, And Few But Well-funded Startups
January 20, 2016

2015 was the biggest year ever for venture capital funding into the biotech sector. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $7.4B was invested during the year.  Lots

Leave a comment

El Niño At The JP Morgan Conference: Optimism After A Stormy Week For The Biotech Markets
January 15, 2016

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. The wifi is predictably not working on my flight back from the JP Morgan Healthcare Conference (#JPM16), allowing me the

Leave a comment

Sentiments Likely To Be Overheard At #JPM16
January 8, 2016

It’s that time of the year again.  As part of the annual pilgrimage, acolytes of the healthcare investment community are about to descend upon the Union Square area of San Francisco. As part of the ritual of the 34th Annual

Leave a comment

This Time May Be Different: Today’s Biotech Market In Context
January 7, 2016

The past five years have been the greatest bull run in the history of the biotech industry. Stock market outperformance, significant fundraising levels both private and public, more IPOs in this window than ever before, and huge volumes of M&A.


Neuroscience Deal Doublet: Both Quartet and Rodin Strike Transformative Partnerships
January 6, 2016

We’re excited to announce two new collaborations today from our neuroscience portfolio – Quartet with Merck (here) and Rodin with Biogen (here) – to advance their programs into early clinical development.  These are both young companies that we helped create

Leave a comment

The Virtues of Virtual – And Why We’re Devirtualizing
January 4, 2016

This blog was written by Mike Gilman, CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I stumbled into a bit of a mess a few weeks ago. It was with the best of intentions, of course.